Two patients died (lung cancer and myocardial infarction). At month 12, 93% of the study population had an undetectable HIV RNA viral
load. Hyperbilirubinaemia >3 mg/dL and increased alanine aminotransferase levels>200 IU/L were observed in 38.5% and 4.4% of patients, respectively. Median changes from baseline STAT inhibitor to month 12 in total cholesterol, triglycerides and low-density lipoprotein cholesterol were −13 mg/dL (−7%; P<0.0001), −19 mg/dL (−13%; P<0.0001) and −7 mg/dL (−6%; P=0.021), respectively. In a real-world setting, switching from other PIs to ATV/r is a well-tolerated and safe option for improving the lipid profile and for retaining virological response in controlled pretreated click here patients. Highly active antiretroviral therapy (HAART) has decreased morbidity and mortality in HIV-positive patients, with the result that HIV infection is now an incurable chronic disease [1,2]. Significantly prolonged life expectancy and the availability of active potent antiretroviral (ARV) drugs have changed the way HIV specialists approach HAART [3]. Current treatment guidelines highlight the importance of considering a potential regimen not only for its antiretroviral potency,
but also in terms of how it affects food requirements, adverse events and pill burden, all of which can compromise long-term adherence [4–6]. The degree of adherence to ARV drugs is clearly associated with the outcome of treatment, which depends on sustained reduction in viral load, avoidance of resistance and maintenance of a broad range of treatment options [7]. HAART optimization strategies for virologically controlled patients are common in clinical practice. The ideal simplification regimen should maintain virological suppression while preserving immune function, improve adherence and quality of life, and reduce or prevent adverse events [6,7] such as morphological changes, metabolic events and the potential increase in cardiovascular risk [2,8]. The available simplification strategies [9] include switching from about a protease inhibitor (PI) to a nonnucleoside reverse
transcriptase inhibitor (NNRTI; e.g. nevirapine or efavirenz [10–13]), once-daily dosing [14] and coformulated fixed-dose ARV drug combinations. Atazanavir (ATV) is a highly active azapeptide inhibitor of HIV protease. It was the first PI with a pharmacokinetic profile that allows once-daily oral administration for a variety of patients and indications in HIV therapy [3,15]. Randomized trials in treatment-naïve and treatment-experienced HIV-infected patients demonstrated that regimens containing ATV boosted with ritonavir (ATV/r; 300/100 mg/day) were as efficacious as those containing lopinavir/ritonavir (LPV/r) [16,17]. ATV/r has shown efficacy as a switch option for patients on stable LPV/r-based HAART [18].
Related posts:
- Commercially insured patients with lung cancer when compared with a matched control group
- Eleven patients (55%) died, 9 patients (45%) are alive The 5 yea
- e mimick ing the post myocardial infarction microenvironment, st
- Survival of pomalidomide-treated PMF patients was compared to other PMF patients
- 7 versus 22 1) than patients who never received low-dose corticos